Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 206-210

  Wang, Zhigang ^a   Cai, Haikang ^b   Lin, Lijun ^c   Tang, Mingjie ^d   Cai, Haiqing ^a  

^a SHANGHAI CHILDREN S MEDICAL CENTER   (China)

^b Xuhui Central Hospital   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Clinicopathologic features; MicroRNA 214; Overall survival; Pediatric osteosarcoma; Progression free survival

Indexed keywords

MICRORNA 214;

ADOLESCENT; ADULT; ARTICLE; BONE TISSUE; CANCER PROGNOSIS; CANCER TISSUE; CHILD; CHILDHOOD CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

EID: 84890861930     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24763     Document Type: Article

References (25)

1. Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: A review. Sarcoma 2011; 2011:959248.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152:3-13.
3. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009; 152:467-478.
4. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134:281-297.
5. Papachristou DJ, Papavassiliou AG. Osteosarcoma and chondrosarcoma: New signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol 2007; 39:857-862.
6. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93:98-104.
7. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329:125-136.
8. Osman A. MicroRNAs in health and disease-Basic science and clinical applications. Clin Lab 2012; 58:393-402.
9. Amiel J, de Pontual L, Henrion-Caude A. miRNA, development and disease. Adv Genet 2012; 80:1-36.
10. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012; 45:487-498.
11. Fabbri M, Calore F, Paone A, et al. Epigenetic regulation of miRNAs in cancer. Adv Exp Med Biol 2013; 754:137-148.
12. Jones KB, Salah Z, Del Mare S, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012; 72:1865-1877.
13. Cai H, Lin L, Cai H, et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol 2013; 30:499.
14. Novello C, Pazzaglia L, Cingolani C, et al. miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 2013; 42:667-675.
15. Xu CX, Xu M, Tan L, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 2012; 287:34970-34978.
16. Li X, Zhang Y, Zhang H, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 2011; 9:824-833.
17. Zhang XJ, Ye H, Zeng CW, et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010; 3:46.
18. Wang X, Chen J, Li F, et al. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun 2012; 428:525-531.
19. Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat 2012; 33:551-560.
20. Qiang R, Wang F, Shi LY, et al. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 2011; 43:632-641.
21. Huvos AG. Osteosarcoma in adolescents and young adults: New developments and controversies. Commentary on pathology. Cancer Treat Res 1993; 62:375-377.
22. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221-1230.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
24. Penna E, Orso F, Cimino D, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011; 30:1990-2007.
25. Schwarzenbach H, Milde-Langosch K, Steinbach B, et al. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 2012; 134:933-941.